FDA approves first standalone nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Healio31m
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Hosted on MSN11m
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
BioSpace36m
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
WCCB53m
FDA approves standalone nasal spray for depression
A new nasal drug has been approved to treat depression. The drug Spravato  is a nasal spray made by Johnson and Johnson.
The hyperloop is not only possible, but on the way to becoming reality
The hyperploop — a near vacuum tube where pods would travel inside via magnetic levitation at hundreds of miles per hour — could make the trip between Pueblo and Denver just 10 minutes.